NHLBI StARR NOW RECRUITING SCHOLARS FOR 2024-2025 AND BEYOND.
Our NHLBI-funded StARR program is designed to support residents interested in clinical or translational research to improve prevention, detection, or management of cardiovascular, pulmonary, or hematologic health conditions.
Research, Mentorship and Training
StARR Support and Benefits
The StARR program covers 80% of residents' salaries during their StARR year and provides funds to support didactic training in research. The other 20% of residents' salaries, as well as all of their benefits, are covered by their residency programs or departments.
Resident scholars also have access to additional research support funds, travel/conference funds, workspace in UCSF Mission Hall and support from statisticians in the Department of Epidemiology & Biostatistics.
Successful StARR graduates are also eligible to apply for new Transitions from StARR K38 grants from the NHLBI that can provide future salary and research support after completion of StARR. Graduates can carry these NIH funds on to other institutions, if desired.
Timing of StARR support
Residents may pursue StARR at different times in their postdoctorate training depending on their clinical background. For example:
- Pediatrics: Residents can pursue StARR either through an additional (PGY4) year of training (via the "extended residency" StARR pathway) or by substituting a StARR year (via the short-track StARR pathway) for the usual PGY3 year.
- Medicine: Residents can pursue StARR through an additional (PGY4) year of training.
- Clinical Pathology/Laboratory Medicine: Residents may pursue StARR after completing two years of clinical residency training.
- Anesthesia: Residents may pursue StARR during either their PGY4 or PGY5 year as part of the residency's Research Scholars Track.
- General Surgery: Residents may pursue StARR during one of their two dedicated research years (usually after their PGY3 year).
Eligibility and Selection
To be eligible for the UCSF StARR program, residents should:
- Be currently enrolled in a UCSF residency (Non-UCSF residents are not eligible to join the UCSF StARR program.)
- Be a US citizen or a permanent US resident
- Show evidence of interest in clinical or translational research (specific prior research experience in cardiovascular, pulmonary or hematologic health is desirable but not required.)
- Have a strong interest in conducting research related to an aspect of cardiovascular, pulmonary or hematologic conditions
- Belong to a residency program or department that will co-sponsor their participation, including 20% salary and all benefits during the StARR year
Of note, the departments of Medicine, Pediatrics, Anesthesia, Surgery, Laboratory Medicine, Emergency Medicine, and Obstetrics & Gynecology have already confirmed co-support of their residents selected for StARR.
Scholar selection process
Scholar selection is designed to identify the most promising candidates as well as guide candidates in identifying mentors and developing preliminary research plans before the start of the StARR year. This approach ensures that residents begin the StARR program with at least one committed research mentor and a preliminary research plan already in place.
Residents are encouraged to contact co-Program Director Dr. Alison Huang for a preliminary informal consultation prior to submitting an application. Following this, promising candidates will pursue a two-stage application process:
Stage 1
During stage 1, by the summer or fall before the proposed StARR year (i.e., summer of 2023 for a residents seeking to join StARR in the summer of 2024), applicants submit:
- A one-page cover letter describing their clinical and research background, any prior research training, and current or future research interests
- A resume or curriculum vitae emphasizing any past research training, experience, or products
- A brief statement of eligibility/support from the applicant’s residency director (see template)
Preferred format is PDF.
Stage 2
Following review of materials from stage 1, promising applicants will be guided in preparing additional materials by the spring before the start of the StARR year, to ensure they have viable StARR research and training plans.
An online form will be sent to applicants to complete and attach required documents. All documents must be in PDF format. These include:
- A letter of support from the proposed primary research mentor confirming interest in and ability to mentor the resident. If an additional secondary mentor or co-mentor has been identified, the applicant should include a brief letter from the co-mentor as well.
- A 2-3-page research proposal synopsis describing the objectives, methods and expected outcomes of a proposed project (with input from the primary mentor)
- An NIH-style biosketch summarizing education/training, research goals and any past contributions to science or research support
- A brief training plan, describing any methodological or career development activities that the resident proposed to pursue during the StARR year
Before appointments are confirmed, stage 2 applications are reviewed by the Program Directors and Steering/Advisory Committee, who consider the qualifications of the resident, the experience or resources of the mentor, and the appropriateness of the research plan.
Residents from internal medicine or pediatrics seeking to pursue StARR via the short-track pathway are strongly encouraged to make preliminary inquiries by the end of internship, to ensure that they can pursue a program of clinical care and research that will lead to board eligibility.
StARR Cohorts
2024-2025
Name | Department | Project Title |
Nyasha Chagwedera, MD, PhD | Adult Psychiatry | Assessing the Feasibility and Acceptability of the Reduction of Ultra-Processed Foods from the Diets of a Subset of Patients with Depression and High Cardiac Disease Risk - A Pilot Open-Label Crossover Trial |
Axel Gomez Casarez, MD | General Surgery | Application of a Patient Specific Biomechanical Model for Enhanced Prediction of Behavior and Outcomes of Ascending Thoracic Aortic Aneurysms |
Jessica Santos-Parker, MD, MS, PhD | Surgery | Disparities in Lung Cancer Screening |
Gerald Tiu, MD, PhD | Pediatrics | Effect of Donor Clonal Hematopoiesis on Pediatric Transplant Alloimmunity and Outcome |
2023-2024
Name | Department | Project Title |
Joanna Balcerek, MD, PhD | Laboratory Medicine | Exploring the Regulatory T Cell Niche in Adipose Tissue During Obesity |
Joel Ramirez, MD | Vascular and Endovascular Surgery | Mapping Immune Cell Expression Patterns in Abdominal Aortic Aneurysms with Spatial Single Cell Sequencing |
2022-2023
Name | Department | Project Title |
Matt Murrill, MD, PhD | Pulmonary and Critical Care |
Multi-Faceted Intervention to Improve the Latent Tuberculosis Care Cascade of non-US born Asians in California: A Quasi-Experimental Study |
2021-2022
Name | Department | Project Title |
David Dillon, MD, MPH, PhD | Emergency Medicine | Opioid-Associated Cardiac Arrest: Epidemiology and Identification |
Ayca Erkin-Cakmak, MD, MPH | Pediatrics | The Interplay Between Iron Load and Endocrinopathies in Patients with Thalassemia |
Andrew Levine, MD, PhD | Hematopathology | Elucidating Ribosome Function in Acute Myeloid Leukemia with Mutated NPM1 |
Katherine Sanders, MD | Surgery | Cost Effectiveness of Abdominal Aortic Aneurysm Repair in Vulnerable Populations |
2020-2021
Name | Department | Project Title |
Mark Barry, MD | General Surgery |
Mitigating vascular dysfunction and lung injury in trauma with human blood products in a murine model of trauma/hemorrhagic shock |
Greg Goldgof, MD, PhD, MS | Clinical Pathology / Laboratory Medicine | Deep learning for real-time cell classification in clinical bone marrow aspirates |
James Salazar, MD, MAS | Internal Medicine | Postmortem systematic investigation of sudden inpatient death attributable to cardiac arrest |
Sam Schnittman, MD | Internal Medicine | Immunologic predictors of myocardial infarction in people with HIV |
2019-2020
Name | Department | Project Title |
Sagar Bapat, MD, PhD | Laboratory Medicine |
Elucidating the role of nuclear hormone receptor peroxisome proliferator activated receptor gamma (PPARg) in obesity-associated T helper 2 cell immunopathology in asthma |
David Blair, MD, PhD | Pediatrics | Expanding the known genetic architecture of hereditary hemorrhagic telangiectasia by leveraging biobank-scale genotype and phenotype data |
Leslie Suen, MD | Internal Medicine | Measuring relationships between self-reported cocaine use against blood pressure and cardiac troponin in homeless and unstably housed women |
Jeffrey Whitman, MD, MS | Laboratory Medicine | Improving Chagas disease diagnosis: serologic, metabolomic, and proteomic characterization of Trypanosoma cruzi infection for novel diagnostic development |
StARR Leadership
StARR FAQs